tombal
@bertrandtombal
ID: 1332642239248539648
28-11-2020 11:08:00
191 Tweet
711 Followers
126 Following
Gain insight into factors determining treatment appropriateness in high-risk non-metastatic #ProstateCancer 📌Check out our new case-based #CME course: ppcp.mirrorsmed.org/en/topic/pzo0k… 📽️ Including 2 cases with a video discussion by Johan Stranne Vérane Achard OncoAlert
🚨Risk Stratification of Patients with Recurrence After Primary Treatment for #ProstateCancer🚨 European Urology ✍️Systematic Review of prospective data 👉Recurrence after PCa tx can be difficult to prognosticate Risk factors w/ at least moderate evidence include:
All Biochemical Recurrences Are Equal, but Some Are More Equal than Others sciencedirect.com/science/articl… A honor to comment on the superb review by Adam B. Weiner, MD Vérane Achard European Urology
tombal discussing the Key point to consider a de-escalation strategy in mCSPC! 👉 Why! Who! How ! When!! GUARD Consortium Asociación Argentina de Oncología Clínica (AAOC) #GUARDSymposium2024 Piet Ost Advanced Prostate Cancer Consensus Conference silke gillessen David Olmos Dra. María Natalia Gandur Quiroga Elena Castro
#GUARDSymposium2024 Amazing talk by tombal about de-escalation of systemic treatment in advanced PCa: ➡️How? ➡️Who? ➡️When? OncoAlert OncoReporte Ana Paula Garcia Cardoso David Muniz David Muniz Marcelo Wroclawski Stephen Freedland, MD #OncoAlert #OncoReporte
Darolutamide outcomes in #European patients with #mHSPC from the #ARASENS trial. tombal UCLouvain joins Alicia Morgans, MD, MPH Dana-Farber in this discussion on UroToday > bit.ly/4aODZfQ
Is There a Place for De-escalating Therapy in Patients with Metastatic...The answer is clinical trials.... silke gillessen Fabio Turco aurelius omlin Advanced Prostate Cancer Consensus Conference EORTC GUCG YI EORTC sciencedirect.com/science/articl…
EORTC is pleased to announce that the primary endpoint has been reached in the EORTC-1333-GUCG/PEACE III Trial. eortc.org/blog/2024/07/1… silke gillessen tombal Unicancer CancerTrialsIreland 🌈 LACOG - Latin American Cooperative Oncology Group Canadian Urological Association
Darolutamide outcomes in #European patients with #mHSPC from the #ARASENS trial. tombal UCLouvain joins Alicia Morgans, MD, MPH Dana-Farber in this discussion on UroToday > bit.ly/4aODZfQ
The endless debate in patients with BCR after radical treatment: Do Not EMBARK on When, If the Answer Is How | Journal of Clinical Oncology . ascopubs.org/doi/10.1200/JC… Gianluca Giannarini
tombal Gianluca Giannarini Thanks for keeping the debate alive! Let us question the When as well as the How. BCR is a tough space that deserves its own designs and endpoints, and a nuanced approach with patients. Ravi A Madan M.D. ascopubs.org/doi/10.1200/JC…
#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients Dr Shaun Tolan Alison Tree 💙 Clive Peedell Dr. Andrew Loblaw Prof Emma Hall Prof Joe O'Sullivan authors.elsevier.com/sd/article/S03…
Late Breaking Results from the EORTC 1333/PEACE III phase III trial at #ESMO24 eortc.org/blog/2024/09/1… Gustave Roussy Unicancer tombal GETUG; LACOG - Latin American Cooperative Oncology Group; silke gillessen #CancerResearch #ClinicalTrials #Oncology